BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37950153)

  • 1. High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy.
    Dong Y; Zheng M; Wang X; Yu C; Qin T; Shen X
    BMC Cancer; 2023 Nov; 23(1):1097. PubMed ID: 37950153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer.
    Zhu C; Wang S; Du Y; Dai Y; Huai Q; Li X; Du Y; Dai H; Yuan W; Yin S; Wang H
    BMC Gastroenterol; 2022 Oct; 22(1):437. PubMed ID: 36253721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumors.
    Zhang D; Wang T; Zhou Y; Zhang X
    Medicine (Baltimore); 2023 Apr; 102(14):e33468. PubMed ID: 37026918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Profiling Identifies
    Shi J; Bao M; Wang W; Wu X; Li Y; Zhao C; Liu W
    Front Immunol; 2021; 12():722807. PubMed ID: 34646265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1.
    Noh JY; Lee IP; Han NR; Kim M; Min YK; Lee SY; Yun SH; Kim SI; Park T; Chung H; Park D; Lee CH
    Cell Mol Gastroenterol Hepatol; 2022; 14(4):769-788. PubMed ID: 35843546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of transient receptor potential channels-related signature for prognosis, tumor immune microenvironment, and treatment response of colorectal cancer.
    Wang L; Chen X; Zhang H; Hong L; Wang J; Shao L; Chen G; Wu J
    Front Immunol; 2022; 13():1014834. PubMed ID: 36389750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
    Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer.
    Wang D; Liufu J; Yang Q; Dai S; Wang J; Xie B
    Biol Direct; 2022 Nov; 17(1):29. PubMed ID: 36319976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer.
    Li YY; Wang XY; Li Y; Wang XM; Liao J; Wang YZ; Hong H; Yi W; Chen J
    Cell Oncol (Dordr); 2023 Jun; 46(3):777-791. PubMed ID: 36920728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer.
    Kuai W; Xu X; Yan J; Zhao W; Li Y; Wang B; Yuan N; Li Z; Jia Y
    Biomed Res Int; 2020; 2020():5294043. PubMed ID: 32509862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children.
    Ruan Y; Xie L; Zou A
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10841-10850. PubMed ID: 37314514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LOXL1 promotes tumor cell malignancy and restricts CD8 + T cell infiltration in colorectal cancer.
    Li C; Chen S; Fang X; Du Y; Guan XY; Lin R; Xu L; Lan P; Yan Q
    Cell Biol Toxicol; 2024 Jan; 40(1):6. PubMed ID: 38267662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma.
    Liang Z; Sun R; Tu P; Liang Y; Liang L; Liu F; Bian Y; Yin G; Zhao F; Jiang M; Gu J; Tang D
    Front Immunol; 2022; 13():944286. PubMed ID: 36591255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer.
    Weixler B; Cremonesi E; Sorge R; Muraro MG; Delko T; Nebiker CA; Däster S; Governa V; Amicarella F; Soysal SD; Kettelhack C; von Holzen UW; Eppenberger-Castori S; Spagnoli GC; Oertli D; Iezzi G; Terracciano L; Tornillo L; Sconocchia G; Droeser RA
    Oncotarget; 2015 Nov; 6(35):37588-99. PubMed ID: 26439988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.